Celgene Corporation Logo

E-mail this page: News Release

Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma

For security reasons, registration is required before you can use this feature.
* Indicates required field